Lyra Therapeutics, Inc. (NASDAQ:LYRA – Get Rating) saw a large growth in short interest in April. As of April 30th, there was short interest totalling 375,600 shares, a growth of 50.0% from the April 15th total of 250,400 shares. Based on an average daily volume of 222,400 shares, the short-interest ratio is currently 1.7 days.
Shares of NASDAQ:LYRA opened at $4.88 on Friday. Lyra Therapeutics has a 1-year low of $3.30 and a 1-year high of $9.98. The business’s 50 day moving average is $5.06 and its 200-day moving average is $5.06.
Lyra Therapeutics (NASDAQ:LYRA – Get Rating) last announced its quarterly earnings data on Wednesday, March 9th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.23). The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $1.00 million. Research analysts expect that Lyra Therapeutics will post -1.67 EPS for the current year.
Several large investors have recently made changes to their positions in LYRA. Citadel Advisors LLC acquired a new stake in shares of Lyra Therapeutics during the 2nd quarter worth approximately $156,000. Two Sigma Advisers LP boosted its stake in Lyra Therapeutics by 31.8% in the 3rd quarter. Two Sigma Advisers LP now owns 58,000 shares of the company’s stock valued at $529,000 after buying an additional 14,000 shares in the last quarter. Pentwater Capital Management LP boosted its stake in Lyra Therapeutics by 122.8% in the 4th quarter. Pentwater Capital Management LP now owns 71,313 shares of the company’s stock valued at $311,000 after buying an additional 39,299 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Lyra Therapeutics in the 4th quarter valued at $227,000. Finally, Clearline Capital LP acquired a new stake in Lyra Therapeutics in the 4th quarter valued at $283,000. 85.06% of the stock is currently owned by institutional investors.
A number of analysts have issued reports on the company. Zacks Investment Research lowered Lyra Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 11th. William Blair reaffirmed an “outperform” rating on shares of Lyra Therapeutics in a report on Tuesday, May 10th.
About Lyra Therapeutics (Get Rating)
Lyra Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.
- Get a free copy of the StockNews.com research report on Lyra Therapeutics (LYRA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Lyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.